KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Impact of ERCC1 on the outcomes of chemotherapy in advanced biliary tract cancer.

Yasunari Sakamoto, Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Nobuyoshi Hiraoka, Tomoki Shirota, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Hiroshi Imaoka, Masato Ozaka, Naohiro Okano, Hironori Yamaguchi, Nobumasa Mizuno, Tomohiro Nishina, Akio Katanuma, Yasushi Kojima, Kunihito Gotoh, Keiya Okamura, Yasuyuki Kawamoto, Kazuya Sugimori, Takeshi Terashima, Rie Sugimoto, Hirofumi Shirakawa, Junji Furuse

Sci Rep 15(1) 33862

PMID41028776
PMCIDPMC12485096
DOI10.1038/s41598-025-07058-7
发表日期2025-10-01
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。
摘要

摘要

The phase III randomized trial, JCOG1113 has demonstrated the non-inferiority of gemcitabine and S-1 (GS) therapy to gemcitabine and cisplatin (GC) therapy for advanced biliary tract cancer (BTC). However, biomarkers for favorable therapy or to predict patient prognosis remain lacking. In this study, we evaluated five candidate biomarkers potentially involved in the efficacy of cisplatin or S-1 by immunostaining tumor specimens obtained from JCOG1113 participants. The participants were randomly divided into training or test sets and classified into high- or low-expression groups based on the cutoff value calculated from the immunostaining results for each biomarker in the training set. Associations between the expression of each biomarker and the outcomes in JCOG1113 were analyzed. Among the 148 eligible participants, no interaction was observed between the treatment arms of GC or GS for any factor or biomarker. However, high excision repair cross-complementing gene 1 (ERCC1) was associated with poor overall survival (HR, 2.226; 95% CI, 1.160-4.272) and progression-free survival (HR, 1.793; 95% CI, 0.945-3.402) compared with low ERCC1 in the training set. Similar trends were observed for the test set. Our results indicate that in advanced BTC, high ERCC1 expression is a poor prognostic factor.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Flowchart of this study from recruitment to the enrollment of the final set of participants.
非 KM Figure
Fig. 2Schema of the evaluation of the association between the five candidate markers of protein expression and survival in this study.
非 KM Figure
Fig. 3Kaplan–Meier survival curves of overall survival and progression-free survival for patients with ERCC1 in a combined (GC arm + GS arm) cohort in the training ( A ) and test sets ( B ).
非 KM Figure